Health News

(MedPage Today) — The maker of the prostate cancer immunotherapy sipuleucel-T (Provenge) has exaggerated the therapy’s efficacy and played down its risks in some marketing materials, the FDA charged.

Read more

Filed under: General Health News
Tags: cancer, General Health News, Prostate Cancer

Related posts

• Why prostate cancer patients fail hormone deprivation therapy (0)
  (Johns Hopkins Medical Institutions) The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to [...]
  
  
• When should PSA testing be stopped? (0)
  Although widespread Prostate-Specific-Antigen (PSA) testing has undoubtedly decreased prostate cancer mortality, is there a point of diminishing returns? Read more [tags] General Health News [/tags]
  
  
• When should prostate-specific antigen testing be stopped? (0)
  (Elsevier Health Sciences) In a study published in the April 2009 issue of the Journal of Urology, researchers found that in a subgroup of elderly men, among those who were 75 years old or older and had a PSA below 3 ng/ml, none subsequently died of prostate cancer. The discontinuation of routine PSA screening in [...]
  
  
• Washington Week: SGR Patch, Lots of FDA Action (0)
  WASHINGTON (MedPage Today) -- Congress passed three health-related bills this week and FDA panels weighed in on drugs for thyroid and prostate cancer, a fecal incontinence product, and a weight-loss device. Read more [tags] General Health News [/tags]
  
  
• Washington Week: SGR Patch, FDA Action (0)
  WASHINGTON (MedPage Today) -- Congress passed three health-related bills this week and FDA panels weighed in on drugs for thyroid and prostate cancer, a fecal incontinence product, and a weight-loss device. Read more [tags] General Health News [/tags]